广东乐心医疗电子股份有限公司 2024 年员工持股计划（草案）摘要 证券简称：乐心医疗 证券代码：300562 广东乐心医疗电子股份有限公司 2024 年员工持股计划 （草案）摘要 二〇二四年四月 广东乐心医疗电子股份有限公司 2024 年员工持股计划（草案）摘 声明 本公司及董事会、监事会全体成员保证本员工持股计划及其摘要内容的 真实、准确和完整，没有虚假记载、误导性陈述或重大遗漏。 2 要 广东乐心医疗电子股份有限公司 2024 年员工持股计划（草案）摘 要 风险提示 特别提示 本部分内容中的词语简称与"释义"部分保持一致。 一、广东乐心医疗电子股份有限公司（以下简称"乐心医疗"、"公司"或"本 公司"）2024 年员工持股计划（草案）须经公司股东大会批准后方可实施，本员 工持股计划能否获得公司股东大会批准，存在不确定性。 二、本员工持股计划设立后将由公司自行管理，但能否达到计划规模、目 标存在不确定性。 三、有关本员工持股计划的具体的资金来源、出资金额、预计规模和具体 实施方案等属初步结果，能否完成实施，存在不确定性。若员工认购份额不足 ，本员工持股计划存在低于预计规模的风险。 四、若员工认购资金较低， ...

乐心医疗 2024 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2024-045 广东乐心医疗电子股份有限公司 第四届董事会第十四会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广东乐心医疗电子股份有限公司（以下简称"乐心医疗"或"公司"）第四 届董事会第十四次会议于 2024 年 04 月 09 日以电子邮件、电话、专人送达等方 式通知全体董事，经全体董事同意豁免本次会议通知时间，会议于 2024 年 04 月 10 日以通讯方式召开。 本次会议应到董事 7 人，实到董事 7 人。会议由董事长潘伟潮先生主持，公 司全体监事、高级管理人员列席了本次会议。 会议召集及召开程序符合《中华人民共和国公司法》等相关法律法规和《公 司章程》有关规定，表决形成的决议合法、有效。 二、董事会会议审议情况 本次会议以书面记名投票方式进行表决，经与会董事们认真审议通过以下决 议： （一）审议通过《关于<2024 年股票期权激励计划（草案）>及其摘要的议 案》 为进一步建立、健全长效激励约束机制，稳固公司高级管理人员、核心技 ...

海通证券股份有限公司关于广东乐心医疗电子股份有限公司 向特定对象发行证券并上市之保荐总结报告书 | 保荐机构名称： | 海通证券股份有限公司 | | --- | --- | | 保荐机构编号： | Z22531000 | 经中国证券监督管理委员会《关于同意广东乐心医疗电子股份有限公司向特定 对象发行股票注册的批复》（证监许可[2020]3233 号）批复，广东乐心医疗电子股 份有限公司（以下简称"上市公司""公司"或"发行人"）向特定对象发行股票 23,998,780 股，每股面值人民币 1 元，每股发行价格 16.48 元，募集资金总额为 395,499,894.40元，扣除发行费用后，实际募集资金净额为人民币385,356,068.13元。 本次发行证券已于 2021 年 3 月 11 日在深圳证券交易所创业板上市。海通证券股份 有限公司（以下简称"保荐机构"或"海通证券"）担任其持续督导保荐机构，持 续督导期间为 2021 年 3 月 11 日至 2023 年 12 月 31 日。 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导性陈 述或重大遗漏，保荐机构及保荐代表人对其真实性、准确 ...

海通证券股份有限公司 | 项目 | 工作内容 | | --- | --- | | （2）发表非同意意见所涉问题及结论意见 | 不适用 | | 7、向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 次 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8、关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 否 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9、保荐业务工作底稿记录、保管是否合规 | 是 | | 10、对上市公司培训情况 | | | （1）培训次数 | 2 次 | | （2）培训日期 | 年 月 年 月 2023 5 22 日/2023 12 | | | 日 21 | | （3）培训的主要内容 | 《上市公司治理与规范运作理 论、实务及案例分析》/《2023 | | | 年度持续督导培训》 | | 11、其他需要说明的保荐工作情况 | 无 | 二、保荐机构发现公司存在的问题及采取的措施 | 事项 | 存在的问题 | 采取的措施 | | ...

乐心医疗 2024 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2024-044 广东乐心医疗电子股份有限公司 关于申报医疗器械注册证获得受理的公告 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到加拿大卫生局 医疗器械部设备许可服务科（Bureau of Licensing Services, Medical Devices Directorate, Health Canada -Santé Canada）的回复，获悉公司申报的电子血压计医 疗器械注册申请事宜已获受理，现将相关内容公告如下： | 产品名称 | 申请事项 | 受理号 | 注册 分类 | 结构组成 | 规格、型号 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | 电子血压 | 首次注册 | 375783 | II 类 | 由主机、袖 | BT106 | 本产品适用于测量臂围 在 22cm-45cm 的成人的 | | 计 | 申请 | | | 带组成。 | （TMB-995-GS) | 血压和脉率，其数值供 | | | | | | | | 诊断参考用。 | 上述 ...

| 产品名称 | 申请事项 | 证书编号 | 注册 分类 | 主要变更内容 | 结构组成 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | 电子血压 | 变更注册 | G10 082800 | IIa 类 | 在产品型号列表中新增 | | 适用臂围为 | | | | | | 产品型号：BBZ32-AA01、 | | 22cm-32cm、 | | | | | | BBZ32-AB01、 | 主要由主机 | 22cm-42cm 的 | | 计 | | 0048 Rev.00 | | BBZ32-BB01、 | 和袖带组成。 | 成人室内测量 | | | | | | BBZ32-DA01、 | | 收缩压、舒张 | | | | | | BBZ32-DB01 | | 压及脉率。 | 乐心医疗 2024 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2024-043 广东乐心医疗电子股份有限公司 关于完成医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股 ...

乐心医疗 2024 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2024-042 广东乐心医疗电子股份有限公司 乐心医疗 2024 年公告 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2024 年 02 月 01 日召开第四届董事会第十二次会议与第四届监事会第十一次会议，审议通过了 《关于回购公司股份方案的议案》，同意公司使用自有资金回购公司股份用于股 权激励或员工持股计划。本次回购拟使用的总金额不低于人民币 2,000 万元（含 本数）且不超过人民币 4,000 万元（含本数），回购价格不高于人民币 16.00 元/ 股（含）。 具体内容详见公司于 2024 年 02 月 01 日 在 巨 潮 资 讯网 （www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告编号：2024- 014）。 2024 年 02 月 07 日，公司披露了《关于首次回购公司股份的公告》（公告 编号：2024-018），具体详见公司在巨潮资讯网（www.cni ...

乐心医疗 2024 年公告 广东乐心医疗电子股份有限公司 关于申报医疗器械注册证获得受理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到美国 FDA 发 出的《Acknowledgement Letter》，获悉公司申报的电子血压计医疗器械 510(k)注 册申请已获受理，现将相关内容公告如下： 上述医疗器械注册申请事宜目前尚处于受理阶段，后续仍需相关部门进一步 核准认证，评审在各阶段所需的时间和结果均具有一定的不确定性。公司目前尚 无法预测其对公司未来业绩的影响，敬请广大投资者注意投资风险。 乐心医疗 2024 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2024-041 | 产品名称 | 申请事项 | 受理号 | 注册 分类 | 结构组成 | 规格、型号 | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | 电子 | 首次注册 | | 类 | 由主机、袖 | | 本产品适用于测量臂围 在 22cm-32cm、22cm | ...

相对估值：11.57-12.03 元 公司主要的应收来自于医疗级设备及可穿戴设备，其中包括与 TWS 耳机、助听器、 医疗检测设备等。目前，缺少和公司业务高速类似的上市公司，我们选择了具有 部分业务重叠的厂商作为可比公司，包括歌尔股份、天健股份、鱼跃医疗。 歌尔股份：公司主要从事声学、传感器、光电、3D 封装模组等精密零组件，以及 虚拟/增强现实、智能穿戴、TWS、机器人等智能硬件的研发、制造和品牌营销。 目前已在多个领域建立了全球领先的综合竞争力。 天键股份：公司有注塑、喇叭、SMT 贴片、成品组装、包装等生产车间，每年可 完成 TWS 耳机/头戴式耳机/入耳式耳机等声学产品超过 2,000 万部。公司建立了 焊接标准、超声标准、点胶标准等成熟的耳机生产工艺和工艺标准。 鱼跃医疗：公司是一家以提供家用医疗器械、医用临床器械和互联网医疗服务为 主要业务的公司，而研发、制造和销售医疗器械产品是公司目前的核心业务，也 是目前公司主要业绩来源。公司器械产品主要集中在呼吸供氧、康复护理、手术 器械、高值耗材、中医诊疗器械、药用贴膏及高分子卫生辅料等领域。 相较于以 TWS 耳机等可穿戴设备为主的可比公司，或是专业做医 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥884.26 million, a decrease of 16.98% compared to ¥1,065.10 million in 2022[38]. - The net profit attributable to shareholders for 2023 was approximately ¥34.37 million, a significant increase of 206.21% from a loss of ¥32.29 million in 2022[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥22.54 million, up 159.93% from a loss of ¥37.55 million in 2022[38]. - The basic earnings per share for 2023 was ¥0.1597, compared to a loss of ¥0.1500 in 2022, marking a 206.47% increase[38]. - The total assets at the end of 2023 were approximately ¥1,556.50 million, reflecting a slight increase of 0.59% from ¥1,547.24 million at the end of 2022[38]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥1,040.60 million, an increase of 2.81% from ¥1,012.06 million at the end of 2022[38]. - The net cash flow from operating activities for 2023 was approximately ¥74.14 million, a decrease of 12.41% from ¥84.65 million in 2022[38]. - The company reported a total net profit of -¥12,098,183.90 in the first quarter, highlighting challenges faced at the beginning of the year[46]. - The company has experienced a negative net profit for the last three accounting years when excluding non-recurring gains and losses, raising concerns about its going concern ability[42]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 1.50 per 10 shares, totaling RMB 32,535,178.20 for the fiscal year 2023[15]. Market Expansion and Strategy - The company is focusing on expanding its overseas market presence, particularly in North America, Europe, and Asia-Pacific, which significantly contributes to its revenue[9]. - The company acknowledges the risks associated with international trade policies and aims to adapt its strategies accordingly to ensure stable overseas operations[9]. - Future outlook includes strategic initiatives for market expansion and potential mergers and acquisitions to enhance growth opportunities[38]. - The company is focusing on expanding its presence in emerging markets such as the Middle East and Latin America while enhancing its local sales and service teams[98]. - The company has established deep collaborations with leading RPM clients in Europe and the US, such as Teladoc and Livongo, indicating strong future growth potential[72]. Product Development and Innovation - The company aims to improve its product development capabilities by investing in high-quality R&D talent and enhancing its hardware laboratory facilities[11]. - The company continues to focus on the development of new products and technologies in the IoT sector, aiming to expand its market presence[38]. - The company has introduced new product categories including smart blood glucose meters and OTC hearing aids, enhancing its health IoT product line[68]. - The company is focused on integrating AI and big data into its healthcare services, aligning with national strategies for health and digital development[64]. - The company has developed a standardized digital health management platform that serves various industries, aiming to reduce costs and enhance operational efficiency[79]. - The company has successfully developed various terminal devices in the remote health sector, including blood pressure monitors and smart scales, leveraging edge computing for enhanced system capabilities[135]. - The company has completed the development of a flagship blood pressure monitor that enhances measurement accuracy and stability, enabling precise measurement of various hypertension types[139]. - The company has developed a wearable ECG product that supports 12 leads, enhancing heart health monitoring capabilities and improving overall competitiveness[143]. Research and Development - R&D investment totaled 10,832.33 million yuan, representing 12.25% of the company's revenue during the reporting period, emphasizing the commitment to innovation[88]. - The company has built a comprehensive capability matrix integrating hardware, sensors, algorithms, big data, AI, and cloud computing to establish a differentiated competitive edge[84]. - The company has completed research on blood pressure measurement technologies tailored for special populations, such as pregnant women and diabetics[149]. - The R&D team has focused on improving sensor precision for household electronic scales, achieving a target accuracy of 1%[149]. - The company aims to leverage AI in ECG analysis to enhance product competitiveness and overall market strength[143]. Cost Management and Efficiency - The company is implementing cost control measures to mitigate risks associated with rising raw material and labor costs[12]. - The overall cost of sales decreased by 24.86% to ¥812.72 million, reflecting a strategic focus on cost management[126]. - The company is implementing cost reduction and efficiency improvement strategies, optimizing production processes and supply chain management to enhance competitiveness[112]. Regulatory Compliance and Certifications - The company has received Class II medical device certification for several products, including electronic blood pressure monitors and smart ECG patches, ensuring compliance with regulatory standards[67]. - The company has obtained FDA registration for multiple electronic blood pressure monitors, including models TMB-986 and TMB-987, which are used for measuring systolic and diastolic blood pressure and pulse rate[163]. - The company has received CE certification for its electronic blood pressure monitors, with the latest certification valid until May 26, 2024, indicating compliance with European health and safety standards[166]. Government Support and Subsidies - The company reported a government subsidy of ¥8,397,619.21 in 2023, which is crucial for its operational support[50]. - The company received government subsidies amounting to ¥9,080,006.87, which accounted for 27.42% of total profit[171]. Cash Flow and Financial Management - The net cash flow from operating activities decreased by 34.32% to ¥955,198,924.67 in 2023 compared to ¥1,454,232,776.21 in 2022[169]. - The net cash flow from investing activities increased significantly by 214.01% to ¥1,152,605,295.64 in 2023 from ¥367,060,688.00 in 2022[169]. - The net cash flow from financing activities turned negative, with a net outflow of ¥11,400,033.99 in 2023, a decrease of 110.62% compared to a net inflow of ¥107,375,553.72 in 2022[169]. Market Trends and Projections - The global medical device market is projected to grow from approximately $570 billion in 2022 to $884.8 billion by 2030, with a compound annual growth rate (CAGR) of 5.8%[55]. - The Chinese medical device market reached ¥957.3 billion (approximately $133 billion) in 2022, accounting for 23.3% of the global market[55]. - The wearable medical device market in China is expected to reach ¥144.16 billion by 2025, with a CAGR of 21.9%[56]. - The digital healthcare market in China is projected to reach RMB 284.4 billion in 2023 and further grow to RMB 413 billion in 2024, indicating a significant expansion in the sector[60]. - The global telemedicine market reached RMB 12.31 billion in 2022 and is expected to grow at a CAGR of 24.58%, reaching RMB 46.854 billion by 2028[63]. Risk Management - The company is strengthening its foreign exchange risk management to address potential impacts from currency fluctuations on its profitability[13]. - The company has implemented risk control measures, including careful selection of trading counterparties and maintaining a balance between foreign exchange assets and liabilities[183]. Corporate Governance - The company has improved its governance structure and investor relations, enhancing communication with investors through various channels[118]. - The company has strengthened its internal control systems to mitigate risks and enhance operational efficiency[119].